logo-loader
viewSareum Holdings PLC

Small Cap Feast - Sareum Holdings; Red Rock Resources; Instem; Amryt Pharma; Westminster Group; Bango and more...

Sareum Holdings* 0.6p  £18.4m (AIM:SAR) Completion of a fundraising in conjunction with an offer via PrimaryBid. The PrimaryBid Offer successfully completed and closed at 9:00 p.m. on 02 June 2020, raising gross proceeds of £303,722.40 at 0.6 pence per ordinary share. Accordingly, combined with the Placing, the Company has raised a total of £1,022,222.40 (gross) in the Fundraising.

.

Dish of the day

No Joiners Today

Off the menu

No Leavers Today

 

What’s cooking in the IPO kitchen?

 The pantry is bare!

 

Banquet Buffet

Venture Life 70p  £58.6m (AIM:VLG)

AGM Statement. “As outlined on 27th April 2020, we announced the signing of an exclusive EUR168 million agreement with our existing Chinese partner for a number of the Group's products, including Dentyl, with orders in excess of EUR7 million for delivery in 2020.

 

With a robust long-term order book, a strong balance sheet and new commercial opportunities, we look forward to updating the market on our progress as the year progresses.

 

Sareum Holdings* 0.6p  £18.4m (AIM:SAR)

Completion of a fundraising in conjunction with an offer via PrimaryBid. The PrimaryBid Offer successfully completed and closed at 9:00 p.m. on 02 June 2020, raising gross proceeds of £303,722.40 at 0.6 pence per ordinary share. Accordingly, combined with the Placing, the Company has raised a total of £1,022,222.40 (gross) in the Fundraising.

The net proceeds from the Placing, together with approximately £980k of existing cash (as at 31 March 2020) and an estimated R&D tax credit of £150k expected to be received in January 2021, will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes. The Company is targeting the completion of at least one of its TYK2/JAK1 inhibitor preclinical studies in Q4 2020, subject to successful progress.

 

React Group 1.675p  £7m (LSE:REAT)

The cleaning, hygiene and decontamination company has raised £1.25m at 1.5p. Proceeds to be used to

-  strengthen the Company's sales and marketing activities;

-  support a growing contract pipeline and accelerate organic growth; and

-  provide additional working capital and strengthen the Company's balance sheet to support the Company's aspiration to secure larger contracts.

 

Red Rock Resources 0.305p  £2.13m (AIM:RRR)

Update on its joint venture subsidiary Red Rock Australasia Pty Ltd ("RRAL"). The Company through RRAL has applied for four additional gold exploration license areas totalling 916 sq km in the Central Victoria Goldfields of Australia. The applications double RRAL's landholding position to 1,835 sq km and will make it one of the largest tenement holders in the Goldfields. 

The combined applications now cover a 100 km North-South stretch of contiguous tenements centred on the great mining town of Ballarat following historic mining centres and extensive evidence of gold mineralisation throughout. The applications also cover ground to the West along the structural boundary between the Bendigo Zone and the Stawell Zone further West, including ground near another old mining centre, Avoca. The applications now cover a conceptual target area along the structural boundary between the Bendigo Zone and the Melbourne Zone to its East where RRAL has as its near neighbour on both sides the recently listed Canadian explorer Fosterville South (TSX-V:FSX).

 

Instem 540p  £90m (AIM:INS)

Contract with Biotoxtech, a prominent non-clinical Contract Research Organization in South Korea. The contract is worth approximately $1 million, the majority of which will be recognised as revenue in 2020 and the balance in 2021. 

Instem will provide a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions to automate and optimize study related processes at Biotoxtech's R&D facility in South Korea's North Chungcheong Province. Follows FYDec19 results also announced today. Rev +13.7% to £25.7m and adjusted EBITDA £4.9m from £4.1m.

 

Amryt Pharma 138.5p  £214m (AIM:AMYT)

Distribution agreement with Swixx BioPharma AG  of Baar, Switzerland.  

Under the agreement, Amryt has appointed Swixx as exclusive distributor of  Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta ® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.  These represent new territories for the Group providing scope to further accelerate revenue growth, augmenting the sales of Myalepta® already being generated through our existing salesforce in the EU .

 

Creo Medical 175.5p  £276.5m (LON:CREO)

Initial data from the UK's leading user of the Company's Speedboat device demonstrates that the use of Speedboat can save NHS hospitals nearly £5,000 per procedure versus a traditional surgical outcome for patients. Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of £400,000 of NHS funding in just one hospital.

 

Empyrean Energy 5p  £23.6m (AIM:EME)

Update on its Block 29/11, offshore China.

 Highlights

 · 12-month extension to the first phase of exploration on Block 29/11

· The Company now has until 12 June 2022 to drill its first well on Block 29/11

· However, the Company remains committed to safely drilling its first well as soon as practicable

 

Westminster Group 10.9p  £17.4m (AIM:WSG)

The supplier of managed services and technology-based security solutions worldwide, has conducted a successful trial of its fever screening solutions in association with Menzies Aviation and their client, Air France, at Stockholm Arlanda Airport.

 

Using the Westminster fever screening solution, Menzies Aviation will continue to conduct operational trials with Air France and other clients' flights' over the coming weeks in order to fine tune an effective delivery to this added layer of safety and security. Feedback from the first live trial was extremely positive with all passengers screened as they presented their boarding passes at the departure gate. The trial at Stockholm Arlanda Airport is Westminster's first trial at a Scandinavian airport as it looks to widen its client database and airport presence.

 

Bango 162.5p  £120.6m (LON:BGO)

The mobile commerce company, announces that deploying its payment optimization technology has enabled du, the leading UAE mobile operator, to grow its active carrier billing customer base.

Growing the number of customers that activate and use Direct Carrier Billing (DCB), a one-click method of charging purchases to the user's mobile phone bill, is a powerful way for operators to capture more value from the consumption of "OTT" content and services, for example from app stores. Within two weeks of launching the campaign, 20% of the segment had re-engaged and made at least one purchase with carrier billing.

Quick facts: Sareum Holdings PLC

Price: 0.505 GBX

AIM:SAR
Market: AIM
Market Cap: £16.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings raises over a £1mln to advance preclinical work on its...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802. Mitchell says they're exploring the potential benefit of the TYK2/JAK1...

on 4/6/20

5 min read